MMM has a patent application for use of complement inhibition in anticancer therapy.
Introduction
Preventing cancer metastasis is a Holy Grail of cancer therapy, as the majority of cancer deaths are attributed to this process (1) . However, progress in this area has been limited by our poor understanding of its mechanism. Recent evidence has indicated that, in addition to the mechanisms operating in neoplastic cells (2) , alterations in host homeostasis, particularly in the immune system, contribute to metastasis (3) .
These alterations occur in the primary tumor microenvironment (2) , however roles for host-derived cells and mediators at sites distal to the tumor have also been reported (4) .
An important concept in tumor metastasis is the formation of premetastatic niches, in which malignant tumors prepare the environment of remote organs to receive metastatic cells by altering host homeostasis in these organs prior to tumor cell arrival. Since these changes precede metastases, therapeutic targeting of these premetastatic niches might prevent metastasis. The existence of premetastatic niches was proposed over a hundred years ago (3), but only recently have components of these niches been identified and they include myeloid-derived suppressor cells (MDSCs) (5) (6) (7) (8) . The primary tumor hypoxia inducible factors (9) , serum amyloid A3 induced by S100A8 and A100A9 (10) , and S1PR1-STAT3 signaling (11) have been suggested to be involved in recruiting these cells from the bone marrow to premetastatic organs. However, mechanisms governing recruitment of various cells to premetastatic organs and how the cells facilitate metastases are not clear. It is conceivable that MDSCs, which suppress anti-tumor T cell responses in primary tumors and peripheral lymphoid organs (12) , shield metastasizing tumor cells from immune attack at distant sites targeted by metastases (5) . However, in contrast to primary sites, the significance of T cell suppression in premetastatic niches remains unclear (13) . Since the complement anaphylatoxin C5a, a potent chemoattractant in inflammatory reactions (14) , activates and attracts immunosuppressive cells to primary tumors (15) , we hypothesize that C5a also contributes to immunosuppression facilitating metastases in distant sites. 
Materials and Methods

Mice and cell lines
Balb/c wild-type (WT) and C5aR-deficient (C5aR 
Results
C5aR signaling facilitates lung and liver metastases
C5aR-signaling was found to promote tumor growth by modulating anti-tumor immunity in a syngeneic mouse model of cervical cancer (15) . However, its role in metastatic spread of cancer has not been explored. Therefore, we investigated whether C5aR contributes to metastasis. We found that C5aR deficiency reduced lung (Fig. 1A , B) and liver (Supplemental Fig. S1A , B) metastatic burden without significantly affecting the growth of primary breast tumors (Fig. 1C ) in a syngeneic model of breast cancer (4T1), which closely mimics stage IV of human breast cancer (16) . Decreased metastatic burden together with the lack of an impact of C5aR-deficiency on primary tumor growth suggests that C5aR promotes metastasis through mechanisms independent of those operating in primary tumors. In addition, since 4T1 tumor cells do not express C5aR (Supplemental Fig. S1C ), C5aR-signaling in tumor cells does not directly govern metastasis to distant organs. To support our data from genetically modified mice, we examined the impact of pharmacological inhibition of C5aR on metastases in mice bearing GFP-expressing 4T1 breast tumors (4T1-GFP + ). Metastatic burden was markedly reduced in mice treated with C5aR antagonist (C5aRA) compared to placebo treated control mice ( Fig. 1D-F) . Importantly, 75% of the mice that received
C5aRA remained metastases-free (Fig. 1E ), while 25% of the mice developed fewer and smaller lung metastases than control mice (Fig. 1E, F) . Despite this substantial impact on metastasis, similar to observations from the experiments with C5aR knockout mice, pharmacological inhibition of C5aR by C5aRA did not affect growth of the primary tumors in this study (Fig. 1G) . 
C5a regulates the immunosuppressive environment of metastases-targeted organs
The accumulation of immunosuppressive myeloid cells has been reported to be a contributing factor in the formation of premetastatic sites, thereby facilitating metastasis (5, 6) . However, factors regulating the recruitment of these cells to distant sites need to be elucidated. In our previous study in a model of HPV-induced cancer, we demonstrated that C5a acts as a potent chemoattractant of MDSCs to the primary tumors (15) . Thus, we hypothesized that C5a/C5aR also activates and recruits MDSCs to premetastatic niches, resulting in immunosuppression in metastases targeted organs prior to tumor cell arrival. In fact, genetic ( Interestingly, we observed that complement activation, which is associated with C5a generation, occurred in the lungs of breast tumor-bearing mice prior to metastases and significant accumulation of MDSC (Fig. 3D) , since complement C3 fragments were deposited in the lungs as early as at day 4 after tumor implantation (Fig. 3D) . Therefore, we propose that in premetastatic niches, C5a functions as a chemoattractant for MDSCs expressing high levels of C5aR (Fig. 3E) . This hypothesis is supported by the presence of high amounts of C5a in peripheral blood of breast tumor-bearing mice, which increased at later time points (Supplemental Fig. S3A ). Although we observed some increases in C5a levels in BAL, these differences did not reach statistical significance (data not shown). Interestingly, we also found increases in total C3 concentration in plasma (Supplemental Fig. S3B ) and BAL (Supplemental Fig. S3C) suggesting enhanced production of complement fragments in tumor-bearing mice.
Increased expression of genes encoding C3 and C5 in the liver (Supplemental Fig.   S3D ) indicated that this organ is a primary site of C3 and C5 production in tumorbearing mice. In contrast, we did not observe increased expression of C3 and C5 in the lungs (data not shown). Importantly, we did not find enhanced deposition of C3 cleavage fragments and increased expression of C3 and C5 genes (data not shown) in the kidneys that are usually spared from metastasis in this tumor model (16) . We observed deposition of some C3 cleavage fragments limited to the periphery of kidney glomeruli in tumor-free mice with identical staining pattern as reported previously (24) .
The presence of primary breast tumors did not increase this deposition (Supplemental tumor-bearing mice. We determined numbers of cells that produced only one of the examined cytokines, as well as cells that co-expressed both cytokines. Total lung cells were isolated from breast tumor-bearing mice treated with C5aRA or PBS and stimulated ex vivo with the TLR4 agonist lipopolysaccharide (LPS). We found reduction in the amount of CD11b + cells producing only TGF-β in mice treated with C5aRA compared to the PBS group (Fig. 3F) . Relatively low numbers of cytokine-producing cells were observed in total lung cells. Of note, extremely rare hematopoietic stem cell/progenitors have found to be key contributors to the premetastatic niche (7).
Importantly, we found that C5aR inhibition reduced numbers of CD11b + cells that coproduced TFG-β and IL-10 ( Fig. 3G ). TGF-β and IL-10, in addition to facilitating metastasis (26, 27) , are also reported to promote T reg cell generation (28, 29) , thereby suppressing adaptive immunity in the tumor microenvironment (25) . Therefore, we next assessed whether decreased production of these cytokines in mice treated with C5aRA correlated with the reduced numbers of T reg cells in the lungs of mice with primary breast tumors. We found that these mice had lower numbers of T reg cells compared to control mice (Fig. 3H ). This finding was consistent with a reduction in the numbers of T reg cells in the circulation (Fig. 3I) . Thus, we propose that C5aR signaling contributes to immunosuppression in metastases-targeted lungs via recruitment of MDSCs to these sites, regulation of TGF-β and IL-10 expression in these cells and, consequently, generation of T reg cells.
C5aR in MDSCs affects T cell polarization in metastases-targeted organs
We observed that C5aR-deficiency led to Th1 polarization of CD4 + T cells in the lungs of breast tumor-bearing mice (Fig. 4A) . To confirm that C5a impacts generation S1D ). We found that CD4 + T cells differentiated in the presence of lung MDSCs from C5aRA-treated mice displayed increased expression of IFN-γ, resulting in a higher Th1/Th2 ratio compared to a similar setting that used lung MDSC from the PBS group (Fig. 4B, C) . Based on these data, we propose that C5aR signaling contributes to the polarization of CD4 + T cells to a Th2 type in the lungs of tumor-bearing mice by modulating MDSC functions and that disabling C5aR signaling reverses this effect.
Inflammatory changes in the premetastatic niche resemble interstitial pneumonialike inflammation
In addition to the decrease in metastatic burden and decreased MDSC infiltration into the lungs and liver, C5aR-deficiecy (C5aR -/-) markedly attenuated inflammation in these organs. This was demonstrated by reduced inflammatory infiltrates in intraalveolar septa in the lungs (Fig. 5A) , as well as in periportal areas of the liver (Fig. 5 B) .
Morphologic heterogeneity in these infiltrates suggests that, apart from MDSCs, other cells contribute to premetastatic niche formation and recruitment of these cells could be 
inflammation acquired an interstitial 'pneumonia-like' pattern in advanced stages (Fig.   5C ). The diffuse interstitial infiltrates in the lungs were composed of cells resembling granulocytes, with an admixture of small lymphocytes and histiocytes. Occasionally, immature myeloid cells were noted (Fig. 5D ).
In the next set of experiments, we verified that inflammatory alterations of the lungs, observed prior to metastasis in the breast tumor-bearing mice, facilitated seeding of these organs by circulating tumor cells. In these experiments, mice were injected with regular 4T1 cells into the mammary fat pad to create premetastatic niche in the lungs, then these mice and tumor-free control mice were injected i. We observed that lung inflammation in tumor-bearing mice increased seeding of 4T1-GFP + cells in this organ, evident from higher numbers and increased sizes of GFP + metastases in the lungs of mice previously injected with regular 4T1 into the mammary fat pad (Fig. 5E, F, G, H) . Nevertheless, GFP -(non-fluorescent) metastases were also present in these mice (Fig. 5E ) but, by using animal imaging combined with fluorescent microscopy, we were able to distinguish GFP + from GFP -metastases. When these experiments were repeated with 10-fold lower numbers of 4T1-GFP + cells injected i.v., only mice bearing breast tumors developed GFP + metastases in their lungs (Fig. 5I ),
indicating that circulating tumor cells required prior inflammatory changes in the premetastatic niche before effective lung seeding. 
Complement deposition associated with MDSC recruitment may contribute to premetastatic niche formation in breast cancer patients
To determine the clinical significance of our findings, sections of TDLNs from breast cancer patients with invasive, not-otherwise specified (NOS), ductal carcinoma were examined for infiltration by MDSCs and for complement activation (Fig. 6A, B) . In these experiments, MDSCs were identified by co-expression of CD11b + and CD33 + and complement deposition was analyzed as C3 cleavage product deposition (Fig. 6A, B) .
We found accumulation of MDSCs in the TDLNs with breast tumor metastases, as well as in those that were free of metastases, suggesting a correlation with and possible involvement of MDSCs in formation of premetastatic niches in humans. We observed C5aR-expression in those areas occupied by MDSCs (Supplemental Fig. S3F ).
Moreover, complement activation in the TDLNs was observed as extracellular deposition of C3 cleavage fragments in the vasculature and sinuses of these lymph nodes (Fig. 6B ). In addition, we observed production of C3 in the macrophages located in sinuses, as demonstrated by intracellular staining (Fig. 6B) . Intriguingly, both complement deposition and local production of C3 appeared to be higher in the TDLNs where metastases were present (Fig. 6B , right panels vs. left panels).
Discussion
The role of complement in cancer remains uncertain with only a few studies to date reporting on tumor-promoting or tumor-inhibiting properties of complement proteins production of C3. In addition, we found a significant increase in C3 and C5 mRNA levels in the liver after 4T1 tumor inoculation. Therefore, we conclude that an increased concentration of complement fragments in the circulation of tumor-bearing mice is a consequence of increased production in the liver. This rapid onset of activation of the complement cascade is an upstream regulator of the premetastatic niche. C5a generated in this cascade leads to recruitment of MDSCs to the lungs prior to metastases. This function of C5a is similar to its role in recruiting leukocytes to sites of inflammation (14) . Given ubiquitous expression of C5aR on cells of myeloid-origin, other myeloid cells in addition to MSDCs are also likely to be recruited to the premetastatic lungs. Interestingly, the morphological pattern of lung infiltration resembled that of interstitial pneumonia with most of the infiltrating cells present in the intra-alveolar septa.
This type of pneumonitis in humans is difficult to diagnose based on physical examination, however, chest x-ray showing diffuse alveolar opacities or computerized tomography may provide diagnostic clues to premetastatic inflammation.
In addition to recruiting MDSCs, C5a/C5aR signaling stimulated TGF-β and IL-10 production in these cells. Since co-expression of TGF-β and IL-10 contributes to T reg cell generation upon antigenic stimulation (29), we speculate that C5aR signaling in recruited MDSCs regulates this process in premetastatic sites. Our data contrast with recent studies demonstrating inhibitory functions of C5aR in T reg cell generation (38, 39) . This "discordance" is consistent with immunomodulatory functions of C5aR being highly context dependent. In contrast to our study, the previous work was conducted in non-tumor models (38) (39) (40) . In addition, some studies focused on thymus-derived (natural) T reg cells (39) independent experiments, n 1 =9 and n 2 =10 (A, B, C, F, G) or three independent experiments n 1 =8, n 2 =9 and n 3 =10 (E), or one experiment with at least n=8 (D-H, I-L). 
